Genetic Risk Factors Are Not Associated with Wet Age-Related Macular Degeneration Treatment Response to Ranibizumab

被引：0
|
作者：
Chaudhary, Varun [1 ]
Brent, Michael [2 ]
Lam, Wai-Ching [2 ]
Devenyi, Robert [2 ]
Teichman, Joshua [1 ]
Mak, Michael Ying-Kit [2 ]
Kaur, Harneel [1 ]
Barbosa, Joshua [1 ]
Carter, Ronald [4 ]
Farrokhyar, Forough [3 ]
机构：
[1] McMaster Univ, Hamilton Reg Eye Inst, Dept Surg, Div Ophthalmol, Hamilton, ON, Canada
[2] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[3] McMaster Univ, Dept Surg, Hamilton, ON, Canada
[4] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
来源：
OPHTHALMOLOGICA | 2018年 / 239卷 / 04期
关键词：
D O I：
10.1159/000481178
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：240 / 240
页数：1
相关论文
共 50 条
  • [1] Factors Associated With the Response of Age-Related Macular Degeneration to Intravitreal Ranibizumab Treatment
    Yamashiro, Kenji
    Tomita, Kaoruko
    Tsujikawa, Akitaka
    Nakata, Isao
    Akagi-Kurashige, Yumiko
    Miyake, Masahiro
    Ooto, Sotaro
    Tamura, Hiroshi
    Yoshimura, Nagahisa
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2012, 154 (01) : 125 - 136
  • [2] Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
    Dervenis, Nikolaos
    Younis, Saad
    CLINICAL OPHTHALMOLOGY, 2016, 10 : 1117 - 1122
  • [3] Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response
    Chaudhary, Varun
    Brent, Michael
    Lam, Wai-Ching
    Devenyi, Robert
    Teichman, Joshua
    Mak, Michael
    Barbosa, Joshua
    Kaur, Harneel
    Carter, Ronald
    Farrokhyar, Forough
    OPHTHALMOLOGICA, 2016, 236 (02) : 88 - 94
  • [4] Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration
    Yazdi, Mohammad Hossein
    Faramarzi, Mohammad All
    Nikfar, Shekoufeh
    Falavarjani, Khalil Ghasemi
    Abdollahi, Mohammad
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (09) : 1349 - 1358
  • [5] Prognostic Factors of Early Morphological Response to Treatment with Ranibizumab in Patients with Wet Age-Related Macular Degeneration
    Chrapek, Oldrich
    Jarkovsky, Jiri
    Sin, Martin
    Studnicka, Jan
    Kolar, Petr
    Jirkova, Barbora
    Dusek, Ladislav
    Pitrova, Sarka
    Rehak, Jiri
    JOURNAL OF OPHTHALMOLOGY, 2015, 2015
  • [6] GENETIC FACTORS ASSOCIATED WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB IN KOREAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Park, Un Chul
    Shin, Joo Young
    Kim, Sang Jin
    Shin, Eun Soon
    Lee, Jong Eun
    McCarthy, Linda C.
    Newcombe, Paul J.
    Xu, Chun-Fang
    Chung, Hum
    Yu, Hyeong Gon
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (02): : 288 - 297
  • [7] Risk Factors Associated with Earlier Age of Onset of Wet Age-related Macular Degeneration
    Lechanteur, Yara
    van de Camp, Patrick
    Groenewoud, Joannes
    Den Hollander, Anneke
    Klevering, B. Jeroen
    Hoyng, Carel
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [8] Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
    Chen, Youxin
    Han, Fei
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 343 - 351
  • [9] Ranibizumab: Present and Future in the Treatment of the Wet Age-Related Macular Degeneration (Wamd)
    Gimenez Arnau, Jose Maria
    Diaz, Josep Maria
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 37 - 37
  • [10] Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration
    Desideri, Lorenzo Ferro
    Barra, Fabio
    Ferrero, Simone
    Traverso, Carlo Enrico
    Nicolo, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (08) : 735 - 751
12345